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Introduction
(adjusted for renal function) was started in one group of 102 patients within 72 h after receiving a cadaveric New reports in the literature about the effective use of renal allograft and continued for 90 days. One hundred valacyclovir ( Zelitrex°, Valtrex°, Glaxo Wellcome) as and six recipients served as a control group and prophylactic treatment for cytomegalovirus (CMV ) received matching placebo in a similar regimen, also infection in renal transplantation, have prompted us for 90 days. The 408 remaining patients were considto update our recent Editorial Comment (Nephrol Dial ered at moderate risk for CMV disease (CMV positive Transplant 13: 3012-3016, 1998) on this interesting recipients, designated as the sero-positive group) and topic. Valacyclovir not only reduces the incidence of were divided into two equal groups; a valacyclovir active CMV infection and CMV disease in renal trans-treated group and a placebo (control ) group. plant patients, but it also seems to exert a beneficial Treatment in each of the latter groups was respectively effect on the incidence of acute allograft rejection, the same as described above for the high-risk patients. other herpesvirus infections and non-viral infections.
The primary end-point was presumptive CMV disThese additional properties of valacyclovir warrant ease defined as fever occurring in a patient for three a critical analysis of the published data in the light of consecutive days plus leukopenia, thrombocytopenia the old and new available information about ganciclo-or symptoms related to specific organ involvement vir prophylaxis in renal transplantation.
(pneumonitis, hepatitis, …) or constitutional symptoms (myalgia). In an abstract presented at the International Congress on Infectious Diseases in May
Valacyclovir trials
1998, the same authors proposed a definition of CMV disease [3] . Leucopenia was defined as more than two Valacyclovir is an amino acid ester prodrug of acyclovir consecutive leucocyte counts of ∏4000/mm3 or a 30% that is rapidly and almost completely hydrolysed to decrease from baseline; thrombocytopenia was defined acyclovir and has an oral bioavailability of 54% com-as more than two consecutive platelet counts of pared to 20% for acyclovir. The plasma AUC of ∏100 000/mm3 or a 30% decrease from baseline. acyclovir attained with high oral dosage of valacyclovir Pneumonitis was considered if a chest X-ray was (2 g q.i.d.) approximates that of intravenous acyclovir abnormal and consistent with CMV pneumonitis or administration at 10 mg/kg every 8 h [1]. Valacyclovir normal but accompanied by hypoxia. Gastrointestinal in low dose has proven to be as effective as acyclovir in CMV disease was considered present if a patient had the treatment of first and recurrent episodes of genital more than three diarrhoeal stools for more than two herpes simplex virus (HSV ) infection but with a more consecutive days with symptoms of oesophagitis or convenient dosing strategy than the latter.
enterocolitis. CMV hepatitis was indicated by the Lowance et al. recently reported the results of a detection of more than two consecutive elevated alanlarge prospective placebo-controlled trial on the use of ine/aspartate transaminase levels. Retinitis was a diaoral valacyclovir as prophylaxis for active CMV infec-gnosis made through ophthalmological examination.
Alternatively, presumed CMV disease was also any of to therapy with ganciclovir or foscarnet.
Conventional or shell-vial cultures of blood and were considered mild and reversible after dose adjustment. Overall compliance with the protocol was greater urine were used to confirm the presence of CMV. Viral antigen detection (pp-65 antigen) or CMV-DNA-PCR among the patients that received valacyclovir.
The impressive results of this study have to be (polymerase chain reaction) methods were not employed; it is not clear whether immunohistochemical interpreted in the light of current clinical practice. The comparative high incidence of CMV infection (45%) techniques were applied for identification of intranuclear viral inclusion bodies in organ biopsy specimen. and tissue-invasive CMV disease (25%) in the seronegative placebo group are in part, the result of the Standard treatment of an episode of CMV disease consisted of intravenous ganciclovir or foscarnet; it is overall frequent use of induction therapy with OKT3, anti-lymphocyte globulin or anti-thymocyte globulin not mentioned for how many days this therapy was given. Secondary end-points were renal allograft rejec-in the study population (more than 50% of the patients). It is not clarified in this paper exactly when tion, graft function and survival, patient survival, the occurrence of HSV infections, varicella-zoster disease in relation to the CMV infection the acute rejection episodes occurred that made treatment with antiand non-herpesvirus infections. The use of medical resources was also evaluated.
lymphocyte antibodies necessary. As significantly more patients in the sero-negative placebo group received The incidence of laboratory-confirmed CMV disease during the prophylaxis period among the sero-negative monoclonal or polyclonal antibody therapy (29/55) for acute rejection, this chronological relation is recipients was 45% in the placebo group versus only 3% in the valacyclovir group. After 6 months follow-important for the interpretation of the results.
Differences in susceptibility for CMV infection among up the incidence remained unchanged in the placebotreated group at 45% and increased to 16% in the renal transplant recipients are of course not only the result of differences in immunosuppressive drug valacyclovir treated group; the incidence of CMV endorgan disease (tissue invasive CMV disease) in these therapy. More and more experimental evidence becomes available to support a multi-causative model two groups was 25% and 4%, respectively. Recurrent disease was rare; five relapses in the sero-negative of CMV disease development. Several influential factors come into play: TNF-a, IFN-c, gene polymorphplacebo group and two in the sero-negative valacyclovir group.
ism of TNF-a and IL-1 receptor antagonist genes, genetic heterogeneity of cytomegalovirus, coinfection Among the sero-positive recipient groups, the incidence of CMV disease was lower as expected: 0% in the with HHV6, CMV-induced changes in the surface expression of LFA-3 of infected cells, CMV-enhanced valacyclovir group versus 6% in the placebo group at 90 days and 1% and again 6%, respectively, 3 months endothelial ICAM-1 expression, host HLA-type, ….
Also, when comparing the results of this trial with later. Recurrent disease was absent in both seropositive patient groups and only four recipients in the those of other trials, one has to pay attention to the definition of CMV disease that is employed. 'CMV placebo group had evidence of tissue-invasive disease. CMV-related mortality was very low in this study; one disease' as described in this study is the equivalent of 'CMV syndrome' or 'active CMV infection' in other patient succumbed as a result of CMV disease.
The cumulative rate of biopsy-proven acute rejection trials. Except in the instances where symptoms of organ involvement are accompanied by the positive after 6 months was 52% in the sero-negative placebotreated group compared to only 26% in the valacyclo-identification of the virus in the relevant clinical specimen, one cannot speak of CMV disease. Instead the vir-treated group. In the sero-positive groups this difference in acute rejection rate was not statistically authors use the term 'tissue-invasive CMV disease' to signify proven organ involvement and so this term is significant anymore (36% vs 30%, P=0.40) . The incidence of chronic allograft rejection and both graft the equivalent of CMV disease.
Recurrent CMV disease was very infrequent in this function and graft survival as well as patient survival did not differ between the study groups at any time study and occurred only in the sero-negative patient groups (7/208). This finding is in sharp contrast with during follow-up.
The risk of clinical HSV infection was significantly a recent report describing CMV disease recurrence in 31% (103/332) of kidney and simultaneous kidneyreduced in both sero-negative and sero-positive valacyclovir treated groups compared to placebo-groups; also pancreas transplant recipients treated with i.v. ganciclovir therapy for CMV disease followed by 10 weeks the rate of non-herpesvirus infections (e.g. Candida, Staphylococcus) was lower in the sero-negative patients of oral acyclovir as secondary prophylaxis. The most significant clinical risk factors for recurrence in multivthat received valacyclovir.
As a consequence of a lesser rate of CMV disease, ariate analysis were a cadaver organ source and treatment for acute rejection [4] . Recurrence of CMV valacyclovir-treated patients used overall less inpatient medical resources than did the placebo-treated control disease had no effect on the 5-year graft survival and patient survival in this study. patients. Adverse events pertaining to the central nervous system were significantly more frequent in the The finding of a high rate of biopsy-confirmed (52%) and relative steroid-resistant (52.7%, 29/55) acute valacyclovir-treated patient groups. Hallucinations and confusion occurred in a total of 15.7% (48/306) in the rejections in the sero-negative placebo group indirectly points towards an immunological high-risk population. latter groups compared to 3.2% (10/310) in the placebo groups. These drug-related neurological side-effects Furthermore, the fact that only a small proportion of these patients were available for comparative analysis whom low-dose oral valacyclovir (1 g t.i.d.) was successfully employed as pre-emptive therapy for CMV at 6 months (33.9% for CMV disease and 21.6% for biopsy-confirmed acute rejection) remains unexplained. infection in the first patient, and as oral treatment of a CMV recurrence in the second patient. Therapy was The authors conclude that their study population was representative of typical renal transplant recipi-guided by quantitative pp65-antigenaemia detection.
The pp65-antigen test became negative after 3 and 6 ents. However, in the European [5] and Tri-continental Mycophenolate Mofetil Study [6 ] the incidence of weeks of therapy, respectively, and was preceded by the resolution of all clinical symptoms and without biopsy-proven rejection at 6 months (Grade I, II and III using the Banff criteria) in the control group was recurrence after stopping valacyclovir therapy [11] . In a study of 153 pp65-antigen-positive renal transplant respectively, 46.4% (dual therapy with CsA and steroids) and 35.5% (triple therapy with CsA, steroids and recipients Yang et al. showed that all patients with low-grade CMV infection (n=62) had a spontaneous azathioprine). In the European [7] and American Tacrolimus study [8] the incidence of biopsy-proven remission without antiviral therapy. Among the patients with a high-grade CMV infection, the subrejection ('borderline' biopsies excluded) at 12 months in the control group was respectively, 35.9% (CsA group with the greatest risk for CMV disease comprised those patients that received OKT3 treatment without steroids and azathioprine) and 40.0% (CsA, steroids, azathioprine and anti-lymphocyte antibody prepara-ganciclovir prophylaxis; all of them developed active disease (n=6). All other patients with a high-grade tion). These figures compare relatively favourable with the incidence of acute rejection found in the sero-CMV infection had a low incidence of CMV disease [12] . Sagedal et al. confirmed that almost 2/3 of all negative placebo-group in this study, especially when one takes into account the fact that the majority of CMV infections detected by way of a positive pp65-antigen assay in renal transplant recipients at these patients were receiving a triple-drug immunosuppressive treatment together with induction therapy risk for CMV (D+), go in spontaneous remission. The CMV infection tended to last longer in those recipients in more than half of them. The mechanism underlying the potential anti-rejection effect of valacyclovir (1/3) in need of ganciclovir therapy (mean 28 vs 14 days) [13] . These findings emphasize the caution one remains unclear. The fact that no difference in acute rejection incidence was seen between the sero-positive has to observe when interpreting treatment 1 results and using the pp65-antigen detection method as theraplacebo group and the sero-positive valacyclovir group suggests that valacyclovir as such, has no important peutic 2 guidance. intrinsic immunosuppressive effect. The authors imply that the prevention of CMV disease and acute rejection Ganciclovir trials may be related. Upholding this explanation proves difficult regarding the fact that the efficient use of other prophylactic anti-CMV drugs is not associated with a More scientific evidence has recently become available on the use of oral ganciclovir prophylaxis in renal and significant reduction of the acute rejection rate.
The substantial reduction of the acute rejection rate other solid organ transplantation. In heart, lung and liver allograft transplantation, oral ganciclovir prophyin the valacyclovir treated group remains a remarkable result that warrants to perform in the future analogous laxis has also proven to be effective [14] [15] [16] .
Other reports reveal less successful application of trials in which new immunosuppressive drugs like tacrolimus, MMF and rapamycine are used.
ganciclovir prophylaxis in immunologic high-risk renal allograft recipients with a D+/R− CMV-status [17] . The diminished host defense induced by CMV infection is indirectly illustrated by the fact that valacyclovir In this study patients that were considered to have a high immunologic risk (re-transplantation, delayed therapy also reduced the incidence of non-herpesvirus infections. The independent role of CMV as a risk graft function, acute rejection) were switched from azathioprine to MMF therapy as part of a triple factor for invasive fungal disease was recently also confirmed in the setting of orthotopic liver transplanta-immunosuppressive drug scheme (CsA microemulsion, steroids). They were matched by D+/R− controls tion [9] . The CMV-mediated induction of TGF-b production was shown in a rat model and might without high immunologic risk. CMV prophylaxis of 3 weeks of i.v. ganciclovir followed by 9 weeks of oral contribute to the CMV-related state of immunosuppression [10] . low-dose acyclovir or ganciclovir, was not sufficient to prevent CMV syndrome in 53% of these high risk Roughly one out of every six valacyclovir treated patients suffered from neurological side-effects, mostly patients (vs 10% in the control group) and tissueinvasive CMV infection in 12% (vs 0% in the control hallucinations or confusion. This rather high frequency of central nervous system symptoms is of course related group). The authors suggest a possible role of MMF in this failure of CMV prophylaxis. These data, howto the high dosage of the drug required in order to obtain adequate plasma-levels. Therefore, future trials ever, confirm that re-transplantation and acute rejection are risk factors for primary CMV infection. In testing a reduced dose of valacyclovir (1 g t.i.d.) are underway and will probably attain improved results in the high-risk group almost half of the patients had a steroid-resistant acute rejection episode but it is not this respect.
In a letter to the editor, Himmelmann and his clear whether anti-lymphocyte antibody (ALA) preparations were used as treatment.
And if so what type colleagues presented two renal transplant patients in of CMV-prophylaxis was administrated during this of valacyclovir on acute allograft rejection must be anti-rejection therapy. The same authors reported in a further substantiated by additional prospective conprevious article that i.v. GCV prophylaxis is effective trolled trials in which newer immunosuppressive drugs in preventing CMV infection in D+/R− recipients like MMF, tacrolimus and rapamycine are studied. and in CMV-positive recipients treated with ALA [18] .
